This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Prospective Trial of Frozen-and-Thawed Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection

This study is currently recruiting participants.
See Contacts and Locations
Verified July 2015 by McMaster University
Sponsor:
Collaborator:
St. Joseph's Healthcare Hamilton
Information provided by (Responsible Party):
McMaster University
ClinicalTrials.gov Identifier:
NCT02394275
First received: March 10, 2015
Last updated: July 8, 2015
Last verified: July 2015
  Purpose
The primary goal of this proposal is to study the outcome of patients with recurrent Clostridium Difficile Infection (CDI) treated with frozen Fecal Microbiota Transplantation (FMT) in an open-labelled controlled trial. The specific objectives are to evaluate the safety of FMT and to determine the clinical response, treatment failure and relapse rate in patients treated with frozen-and-thawed FMT; to assess the functional health and well-being of patients in each arm using the validated tool, and to determine the feasibility of providing standardized FMT in multiple centres across Canada, including community hospitals. The metagenomics will also be conducted from the stool samples collected from select patients from each arm: pre and post treatment and the matching donors. The metagenomics data will be used to determine the bacteria which may have contributed to the cure of CDI.

Condition Intervention Phase
Clostridium Difficile Biological: Fecal Microbiota Transplant Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective Open-Labelled Multi-Centre Trial of Frozen-and-Thawed Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection

Resource links provided by NLM:


Further study details as provided by McMaster University:

Primary Outcome Measures:
  • cure rate of CDI following FMT [ Time Frame: 13 weeks ]
  • safety of FMT as measured by any significant adverse events, including serious adverse events (SAE) [ Time Frame: 13 weeks ]
    determining any significant adverse events, including serious adverse events (SAE) For each significant event, causality to FMT will be determined by investigators and the DSMB


Secondary Outcome Measures:
  • Mortality rate directly attributable to CDI [ Time Frame: week 13 ]
  • Long-term safety of FMT as measured by questionnaire [ Time Frame: 10 years ]
    Annual follow-up


Estimated Enrollment: 300
Study Start Date: March 2015
Estimated Study Completion Date: May 2025
Estimated Primary Completion Date: March 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Single arm:
Eligible patients with receive intervention: frozen fecal microbiota transplantation (FMT), kept at -20 oC and will be thawed prior to administration. Patients on antibiotic to control CDI will discontinue antibiotic 24 hours prior to FMT.
Biological: Fecal Microbiota Transplant
All eligible patients will receive fecal microbiota transplant
Other Name: Human Biotherapy

Detailed Description:

CDI is the most frequent cause of healthcare-associated infectious diarrhea in industrialized countries and affects over 300,000 patients each year in the United States. The incidence of CDI has nearly tripled between 1996 and 2005 (from 31 to 84 per 100,000 patient-days) in the United States. The rise in incidence has been accompanied by an increase in disease severity, with mortality in up to 6.9% of cases. According to the Canadian Nosocomial Infection Surveillance Program study conducted from November 1, 2004 through April 30, 2005, the incidence rate of health care-associated CDI for adult patients admitted to Canadian hospitals is 65 per 100,000 patient-days. The same study identified that the overall and attributable mortality of patients with CDI is 16.3% and 5.7%, respectively in Canada, which is similar to the US data.1,17 The associated economic burden has also been significant. Nosocomial CDI increases the cost of otherwise matched hospitalizations by four-fold, translating to greater than $1 billion/year (United States). Since the implementation of mandatory reporting of CDI cases in September 2008 in Ontario, more than 13 health-care facilities declared CDI outbreak in Ontario. There were a number of deaths directly due to CDI in these outbreaks. The management of each outbreak is very costly. The direct attributable costs associated with the outbreak management alone per episode per institution exceeded $1 million (direct communication with a hospital chief financial officer).

There is a growing concern regarding failure of standard antimicrobial therapy. The treatment failure rates for metronidazole, which is the first line therapy for uncomplicated CDI, have risen from 2.5% to greater than 18% since 2000. Recurrence rates are higher among the elderly, and exceed 50% for those over the age 65.20 Recurrence rates exceed 60% for patients who have failed 3 or more episodes of standard antimicrobial therapies. The vanB gene, which is responsible for conferring vancomycin resistance in Enterococcus has been isolated in clostridia, potentially threatening the future use of vancomycin in CDI.

Given the high failure and recurrence rates using the standard therapy, the principal investigator (PI) of this research proposal has been offering FMT for patients who experienced CDI for longer than 6 months despite multiple courses of metronidazole and oral vancomycin therapy. She began treating patients with recurrent CDI with FMT for the following reasons. First, the patients were not responding to the antibiotic treatment. Second, patients may experience intolerance to metronidazole due to metallic taste, significant nausea and loss of appetite, which can lead to further weight loss as patients with CDI experience considerable weight loss. Also, some patients develop irreversible peripheral neuropathy (nerve damage) with long term use of metronidazole. Third, some of the patients with refractory CDI could not afford to continue with oral vancomycin. The cost of oral vancomycin was prohibitive and they were not routinely reimbursed by the public health plan. A 14-day course of oral vancomycin costs $600 and a number of the patients were on this antibiotic for 6 - 18 months at a cost of $7,200 to $21,600 (personal communication with St. Joseph's Healthcare Outpatient pharmacist). The cost of one FMT is approximately $100, which includes the laboratory screening test and the nurse's administration time.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age 18 years or older.
  2. Able to provide informed consent.
  3. Laboratory or pathology confirmed diagnosis of recurrent CDI with symptoms (defined below) within the previous 180 days.
  4. ≥ 2 episodes of CDI within 6 months and/or ongoing symptoms consistent with CDI despite treatment with oral vancomycin at a dose of at least 125 mg 4 times daily for at least 5 days.

Exclusion Criteria:

  1. Planned or actively taking an investigational product for another study.
  2. Patients with neutropenia with absolute neutrophil count <0.5 x 109/L
  3. Evidence of toxic megacolon or gastrointestinal perforation on abdominal x-ray
  4. Peripheral white blood cell count > 30.0 x 109/L AND temperature > 38.0 oC
  5. Active gastroenteritis due to Salmonella, Shigella, E. coli 0157H7, Yersinia or Campylobacter.
  6. Presence of colostomy or ileostomy.
  7. Unable to tolerate FMT or enema for any reason.
  8. Anticipated requirement for systemic antibiotic therapy for more than 7 days during the 12 week study period.
  9. Actively taking Saccharomyces boulardii or probiotics other than yogurt.
  10. No symptoms consistent with CDI, off CDI antibiotic therapy for 3 or more weeks
  11. Severe underlying disease such that the patient is not expected to survive for at least 30 days.
  12. Any condition that, in the opinion of the investigator, that the treatment may pose a health risk to the subject.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02394275

Contacts
Contact: Christine Lee, MD 905-521-6021 clee@mcmaster.ca
Contact: Marek Smieja, MD 905-521-6021 smiejam@mcmaster.ca

Locations
Canada, British Columbia
Vancouver General Hospital Recruiting
Vancouver, British Columbia, Canada
Contact: Ted Steiner, MD         
Canada, Ontario
St. Joseph's Healthcare Hamilton Recruiting
Hamilton, Ontario, Canada, L8N 4A6
Contact: Christine Lee, MD    905-522-4941 ext 33346    clee@mcmaster.ca   
Contact: Thomas Longland, MSc    905-522-1155 ext 34982    tlonglan@stjosham.on.ca   
Principal Investigator: Christine Lee, MD         
Sub-Investigator: Marek Smieja, MD         
Kingston General Hospital Recruiting
Kingston, Ontario, Canada
Contact: Elaine Petrof, MD         
Sponsors and Collaborators
McMaster University
St. Joseph's Healthcare Hamilton
  More Information

Responsible Party: McMaster University
ClinicalTrials.gov Identifier: NCT02394275     History of Changes
Other Study ID Numbers: CDI.FMT.2
Study First Received: March 10, 2015
Last Updated: July 8, 2015

ClinicalTrials.gov processed this record on June 22, 2017